Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


09.10.2017

6 Anticancer Res
4 BJU Int
1 BMC Cancer
2 Br J Cancer
2 Cancer
1 Cancer Lett
1 Cancer Res
1 Endocrinology
1 Eur Urol
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 J Nucl Med
1 J Urol
1 N Engl J Med
2 Nat Rev Urol
1 Oncogene
3 PLoS One
2 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. OBATA H, Shiota M, Akitake N, Takeuchi A, et al
    Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Anticancer Res. 2017;37:5631-5637.
    PubMed     Text format     Abstract available

  2. SHIMIZU D, Yamazaki H, Nishimura T, Aibe N, et al
    Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Anticancer Res. 2017;37:5829-5835.
    PubMed     Text format     Abstract available

  3. MACCHIA G, Siepe G, Capocaccia I, Nguyen NP, et al
    Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study.
    Anticancer Res. 2017;37:5821-5828.
    PubMed     Text format     Abstract available

  4. IWAMA K, Yamazaki H, Shimizu D, Suzuki G, et al
    Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
    Anticancer Res. 2017;37:5755-5760.
    PubMed     Text format     Abstract available

  5. HUTCHINSON J, Marignol L
    Clinical Potential of Statins in Prostate Cancer Radiation Therapy.
    Anticancer Res. 2017;37:5363-5372.
    PubMed     Text format     Abstract available

  6. IZUMI K, Shigehara K, Nohara T, Narimoto K, et al
    Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5559-5564.
    PubMed     Text format     Abstract available


    BJU Int

  7. SAYYID R, Perlis N, Ahmad A, Evans A, et al
    Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.
    BJU Int. 2017;120:76-82.
    PubMed     Text format     Abstract available

  8. MOSCHINI M, Sharma V, Gandaglia G, Dell'Oglio P, et al
    Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    BJU Int. 2017;120:69-75.
    PubMed     Text format     Abstract available

  9. MAMAWALA MM, Rao K, Landis P, Epstein JI, et al
    Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    BJU Int. 2017;120:25-31.
    PubMed     Text format     Abstract available

  10. FRADET V, Toren P, Nguile-Makao M, Lodde M, et al
    Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5alpha-reductase inhibitors.
    BJU Int. 2017 Oct 3. doi: 10.1111/bju.14041.
    PubMed     Text format     Abstract available


    BMC Cancer

  11. WITTMANN D, Mehta A, Northouse L, Dunn R, et al
    TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial.
    BMC Cancer. 2017;17:664.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. ALEKSIC T, Verrill C, Bryant RJ, Han C, et al
    IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  13. BRAADLAND PR, Giskeodegard G, Sandsmark E, Bertilsson H, et al
    Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  14. CAMPODONICO F, Grillo-Ruggeri F, Grimaldi A, Zanardi S, et al
    Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31054.
    PubMed     Text format    

  15. HURWITZ LM, Cullen J
    Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31053.
    PubMed     Text format    


    Cancer Lett

  16. HOANG B, Ernsting MJ, Tang WS, Bteich J, et al
    Cabazitaxel-Conjugated Nanoparticles for Docetaxel-Resistant and Bone Metastatic Prostate Cancer.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30582.
    PubMed     Text format     Abstract available


    Cancer Res

  17. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
    Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
    Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
    PubMed     Text format     Abstract available


    Endocrinology

  18. MASOODI KZ, Eisermann K, Yang Z, Dar JA, et al
    Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
    Endocrinology. 2017;158:3152-3161.
    PubMed     Text format     Abstract available


    Eur Urol

  19. WALZ J
    The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?
    Eur Urol. 2017 Sep 28. pii: S0302-2838(17)30779.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  20. SUJENTHIRAN A, Nossiter J, Charman SC, Parry M, et al
    National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Sep 1. pii: S0360-3016(17)33654.
    PubMed     Text format     Abstract available

  21. AGGARWAL A, Lewis D, Sujenthiran A, Charman SC, et al
    Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study.
    Int J Radiat Oncol Biol Phys. 2017 Aug 24. pii: S0360-3016(17)33774.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. CHEN DY, See LC, Liu JR, Chuang CK, et al
    Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    J Clin Oncol. 2017 Oct 2:JCO2016714204. doi: 10.1200/JCO.2016.71.4204.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. SANO K, Kanada Y, Kanazaki K, Ding N, et al
    Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.
    J Nucl Med. 2017;58:1380-1385.
    PubMed     Text format     Abstract available

  24. IAGARU A
    Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    J Nucl Med. 2017 Sep 28. pii: jnumed.117.198192. doi: 10.2967/jnumed.117.198192.
    PubMed     Text format    


    J Urol

  25. HOUSTON KA, King J, Li J, Jemal A, et al
    Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate-Specific Antigen Screening by Socioeconomic Status and Regions in the US, 2004- 2013.
    J Urol. 2017 Sep 28. pii: S0022-5347(17)77650-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  26. WALLIS CJD, Klotz L
    Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1301-2.
    PubMed     Text format    


    Nat Rev Urol

  27. FENNER A
    Prostate cancer: Resveratrol inhibits the AR.
    Nat Rev Urol. 2017 Oct 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  28. KELSEY R
    Prostate cancer: Foxy-5 in prostate cancer model.
    Nat Rev Urol. 2017 Oct 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncogene

  29. CHANG C, Liu J, He W, Qu M, et al
    A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    PLoS One

  30. KHAN S, Simpson J, Lynch JC, Turay D, et al
    Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients.
    PLoS One. 2017;12:e0183122.
    PubMed     Text format     Abstract available

  31. ROBLES-FERNANDEZ I, Martinez-Gonzalez LJ, Pascual-Geler M, Cozar JM, et al
    Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
    PLoS One. 2017;12:e0185447.
    PubMed     Text format     Abstract available

  32. MURPHY C, Rettedal E, Lehouritis P, Devoy C, et al
    Intratumoural production of TNFalpha by bacteria mediates cancer therapy.
    PLoS One. 2017;12:e0180034.
    PubMed     Text format     Abstract available


    Prostate

  33. ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
    Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
    PubMed     Text format     Abstract available

  34. LI E, Liu L, Li F, Luo L, et al
    PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: